Current therapeutic advances targeting EGFR and EGFRvIII in glioblastoma

Frontiers in Oncology

Hayley Patricia Ellis¹  Kathreena M Kurian¹  Emily ePadfield¹ 

[1] University of Bristol;

关键词: EGFR;    molecular marker;    glioblastoma multiforme (GBM);    EGFRvIII;    EFGR inhibitors;   

DOI  :  10.3389/fonc.2015.00005

来源: DOAJ

【 摘 要 】

EGFR and EGFRvIII analysis is of current interest in glioblastoma- the most common malignant primary CNS tumour, because of new EGFRvIII vaccine trials underway. EGFR activation in glioblastoma promotes cellular proliferation via activation of MAPK and PI3K-Akt pathways and EGFRvIII is the most common variant, leading to constitutively active EGFR. This review explains EGFR and EGFRvIII signalling in GBM; describes targeted therapy approaches to date including tyrosine kinase inhibitor, antibody-based therapies, vaccines and preclinical RNA-based therapies and discusses the difficulties encountered with these approaches including pathway redundancy and intratumoural heterogeneity.

【 授权许可】

Unknown